Marignier R, Hacohen Y, Cobo-Calvo A et al (2021) Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol 20(9):762–772. https://doi.org/10.1016/s1474-4422(21)00218-0

Article  CAS  PubMed  Google Scholar 

Reindl M, Schanda K, Woodhall M et al (2020) International multicenter examination of MOG antibody assays. Neurol Neuroimmunol Neuroinflamm. https://doi.org/10.1212/nxi.0000000000000674

Article  PubMed  PubMed Central  Google Scholar 

Jarius S, Paul F, Aktas O et al (2018) MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation 15(1):134. https://doi.org/10.1186/s12974-018-1144-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jarius S, Pellkofer H, Siebert N et al (2020) Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: results from 163 lumbar punctures in 100 adult patients. J Neuroinflammation 17(1):261. https://doi.org/10.1186/s12974-020-01824-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carta S, Cobo Calvo Á, Armangué T et al (2023) Significance of myelin oligodendrocyte glycoprotein antibodies in CSF: a retrospective multicenter study. Neurology 100(11):e1095–e1108. https://doi.org/10.1212/wnl.0000000000201662

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kwon YN, Kim B, Kim JS et al (2022) Myelin oligodendrocyte glycoprotein-immunoglobulin G in the CSF: clinical implication of testing and association with disability. Neurol Neuroimmunol Neuroinflamm. https://doi.org/10.1212/nxi.0000000000001095

Article  PubMed  PubMed Central  Google Scholar 

Matsumoto Y, Kaneko K, Takahashi T et al (2023) Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids. Brain 146(9):3938–3948. https://doi.org/10.1093/brain/awad122

Article  PubMed  Google Scholar 

Satukijchai C, Mariano R, Messina S et al (2022) Factors associated with relapse and treatment of myelin oligodendrocyte glycoprotein antibody-associated disease in the United Kingdom. JAMA Netw Open 5(1):e2142780–e2142780. https://doi.org/10.1001/jamanetworkopen.2021.42780

Article  PubMed  PubMed Central  Google Scholar 

Carta S, Cobo Calvo A, Armangue T et al (2023) Significance of myelin oligodendrocyte glycoprotein antibodies in CSF: a retrospective multicenter study. Neurology 100(11):e1095–e1108. https://doi.org/10.1212/WNL.0000000000201662

Article  CAS  PubMed  PubMed Central  Google Scholar 

Allison AC (2000) Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology 47(2–3):63–83. https://doi.org/10.1016/s0162-3109(00)00186-7

Article  CAS  PubMed  Google Scholar 

Stamatellos VP, Papazisis G (2023) Safety and monitoring of the treatment with disease-modifying therapies (DMTs) for multiple sclerosis (MS). Curr Rev Clin Exp Pharmacol 18(1):39–50. https://doi.org/10.2174/2772432817666220412110720

Article  CAS  PubMed  Google Scholar 

Jarius S, Aktas O, Ayzenberg I et al (2023) Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: diagnosis and differential diagnosis. J Neurol 270(7):3341–3368. https://doi.org/10.1007/s00415-023-11634-0

Article  PubMed  PubMed Central  Google Scholar 

Akaishi T, Takahashi T, Misu T et al (2021) Difference in the source of anti-AQP4-IgG and anti-MOG-IgG antibodies in CSF in patients with neuromyelitis optica spectrum disorder. Neurology 97(1):e1–e12. https://doi.org/10.1212/wnl.0000000000012175

Article  PubMed  PubMed Central  Google Scholar 

Carta S, Höftberger R, Bolzan A et al (2021) Antibodies to MOG in CSF only: pathological findings support the diagnostic value. Acta Neuropathol 141(5):801–804. https://doi.org/10.1007/s00401-021-02286-3

Article  CAS  PubMed  Google Scholar 

Banwell B, Bennett JL, Marignier R et al (2023) Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD Panel proposed criteria. Lancet Neurol 22(3):268–282. https://doi.org/10.1016/s1474-4422(22)00431-8

Article  CAS  PubMed  Google Scholar 

Hor JY, Fujihara K (2023) Epidemiology of myelin oligodendrocyte glycoprotein antibody-associated disease: a review of prevalence and incidence worldwide. Front Neurol 14:1260358. https://doi.org/10.3389/fneur.2023.1260358

Article  PubMed  PubMed Central  Google Scholar 

Yoshimura S, Isobe N, Matsushita T et al (2013) Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin 4 antibody status. J Neurol Neurosurg Psychiatry 84(1):29–34. https://doi.org/10.1136/jnnp-2012-302925

Article  PubMed  Google Scholar 

Qiu W, James I, Carroll WM et al (2011) HLA-DR allele polymorphism and multiple sclerosis in Chinese populations: a meta-analysis. Mult Scler 17(4):382–388. https://doi.org/10.1177/1352458510391345

Article  PubMed  Google Scholar 

Bruijstens AL, Wong YYM, van Pelt DE et al (2020) HLA association in MOG-IgG- and AQP4-IgG-related disorders of the CNS in the Dutch population. Neurol Neuroimmunol Neuroinflamm. https://doi.org/10.1212/nxi.0000000000000702

Article  PubMed  PubMed Central  Google Scholar 

Grant-Peters M, Passos GRD, Yeung HY et al (2021) No strong HLA association with MOG antibody disease in the UK population. Ann Clin Transl Neurol 8(7):1502–1507. https://doi.org/10.1002/acn3.51378

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun X, Qiu W, Wang J et al (2020) Myelin oligodendrocyte glycoprotein-associated disorders are associated with HLA subtypes in a Chinese paediatric-onset cohort. J Neurol Neurosurg Psychiatry 91(7):733–739. https://doi.org/10.1136/jnnp-2019-322115

Article  PubMed  Google Scholar 

Virolainen SJ, VonHandorf A, Viel K et al (2023) Gene-environment interactions and their impact on human health. Genes Immun 24(1):1–11. https://doi.org/10.1038/s41435-022-00192-6

Article  PubMed  Google Scholar 

Jarius S, Ruprecht K, Kleiter I et al (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation 13(1):279. https://doi.org/10.1186/s12974-016-0717-1

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cobo-Calvo A, Sepúlveda M, Rollot F et al (2019) Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. J Neuroinflammation 16(1):134. https://doi.org/10.1186/s12974-019-1525-1

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen JJ, Flanagan EP, Bhatti MT et al (2020) Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology 95(2):e111–e120. https://doi.org/10.1212/wnl.0000000000009758

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sutton P, Lutz MW, Hartsell FL et al (2022) Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: presentation and outcomes of adults at a single center. J Neuroimmunol 373:577987. https://doi.org/10.1016/j.jneuroim.2022.577987

Article  CAS  PubMed  Google Scholar 

Trewin BP, Brilot F, Reddel SW et al (2025) MOGAD: a comprehensive review of clinicoradiological features, therapy and outcomes in 4699 patients globally. Autoimmun Rev 24(1):103693. https://doi.org/10.1016/j.autrev.2024.103693

Article  CAS  PubMed